Given the prevalence of behavioral health issues that often accompany chronic diseases, pairing a pharmacotherapy with a digital therapeutic aimed at driving behavioral change would at first blush seem a natural fit. For example, many psychiatric conditions including depression, anxiety and sleep disorders occur during or as a consequence of treatment of all sorts of diseases. In 2021, psychiatry-related prescription digital therapeutics accounted for 37% of digital therapeutics across all phases of development as well as the majority of digital care programs, according to data from IQVIA.
Digital Health And Pharma Still Defining Rules Of Engagement
Pharma is still searching for how to best bring digital therapeutics on board
Despite all of the buzz around adoption of digital health tools and whopping VC investments in consumer-facing digital health firms, pharma has yet to articulate a business model for co-development or integration of behavior-modifying digital therapeutics into their portfolios.
More from Innovation
More from In Vivo
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.
• By
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.